Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sometimes it really is appendicitis: case of a CML patient with acute appendicitis.

Annals of hematology·1998
Same author

Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans.

Antimicrobial agents and chemotherapy·1998
Same author

Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients.

Leukemia research·1998
Same author

Determinants of increased energy expenditure in HIV-infected women.

The American journal of clinical nutrition·1998
Same author

Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study.

The Journal of clinical endocrinology and metabolism·1998
Same author

Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·1998
Same journal

[Transition in Differences of Sex Development (DSD): From Human Being to Person].

Aktuelle Urologie·2026
Same journal

[Posterior Urethral Valves: A Pediatric Urological Condition with Lifelong Relevance].

Aktuelle Urologie·2026
Same journal

[Current Developments and Strategies for Infection Prevention and Management in Penile Implant Surgery].

Aktuelle Urologie·2026
Same journal

[Transition of Patients with Neurogenic Bladder Dysfunction: Challenges and Unmet Needs in Adult Care].

Aktuelle Urologie·2026
Same journal

[Hypospadias: A Long-Term Problem?]

Aktuelle Urologie·2026
Same journal

[Urogenital Symptoms in Cyclists and Reduction of Perineal Pressure Load Using a Prostate Volume-Adapted Bicycle Saddle].

Aktuelle Urologie·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Castration resistant prostate cancer 2011].

K Miller1

  • 1Urologische Klinik Charité, Berlin, Germany. kurt.miller@charite.de

Aktuelle Urologie
|March 26, 2011
PubMed
Summary
This summary is machine-generated.

Castration-resistant prostate cancer treatment is evolving. New drugs targeting androgen receptor signaling demonstrate that even advanced prostate cancer remains hormone-driven, necessitating updated terminology and therapeutic strategies.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Experiment Videos

Last Updated: Jun 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Prostate cancer treatment paradigms are shifting.
  • The term "hormone refractory" is being replaced by "castration-resistant prostate cancer".

Purpose of the Study:

  • To provide an overview of current drug development in castration-resistant prostate cancer.
  • To discuss therapeutic consequences and future trends in prostate cancer treatment.

Main Methods:

  • Review of recent advancements in prostate cancer drug development.
  • Analysis of clinical data for novel therapeutic agents.

Main Results:

  • New drugs, such as CYP-17 inhibitors (e.g., abiraterone), are effective in castration-resistant prostate cancer.
  • Androgen receptor signaling remains a key driver of progression even in advanced stages.

Conclusions:

  • Castration-resistant prostate cancer is still driven by androgen receptor signaling.
  • Updated understanding necessitates changes in terminology and treatment approaches.